Goldman Sachs initiated coverage of Innoviva (INVA) with a Sell rating and $17 price target The stock’s recent rally has raised the bar for the company’s infectious disease platform platform going forward, the analyst tells investors in a research note. The firm believes Innoviva’s 2031 royalty-related patent cliff will start to weigh on the stock’s performance in 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA: